- Home
- GSL vs AVXL Comparison
GSL vs AVXL Comparison
Compare GSL & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSL
- AVXL
- Stock Information
- Founded
- GSL 2007
- AVXL 2004
- Country
- GSL Greece
- AVXL United States
- Employees
- GSL N/A
- AVXL N/A
- Industry
- GSL Marine Transportation
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GSL Consumer Discretionary
- AVXL Health Care
- Exchange
- GSL Nasdaq
- AVXL Nasdaq
- Market Cap
- GSL 972.2M
- AVXL 794.0M
- IPO Year
- GSL 2006
- AVXL N/A
- Fundamental
- Price
- GSL $28.49
- AVXL $10.82
- Analyst Decision
- GSL Strong Buy
- AVXL Strong Buy
- Analyst Count
- GSL 1
- AVXL 2
- Target Price
- GSL $30.00
- AVXL $44.00
- AVG Volume (30 Days)
- GSL 303.2K
- AVXL 1.2M
- Earning Date
- GSL 08-05-2025
- AVXL 08-15-2025
- Dividend Yield
- GSL 7.34%
- AVXL N/A
- EPS Growth
- GSL 20.64
- AVXL N/A
- EPS
- GSL 10.54
- AVXL N/A
- Revenue
- GSL $715,232,000.00
- AVXL N/A
- Revenue This Year
- GSL $4.15
- AVXL N/A
- Revenue Next Year
- GSL N/A
- AVXL N/A
- P/E Ratio
- GSL $2.68
- AVXL N/A
- Revenue Growth
- GSL 3.83
- AVXL N/A
- 52 Week Low
- GSL $17.73
- AVXL $4.93
- 52 Week High
- GSL $29.23
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- GSL 61.07
- AVXL 49.42
- Support Level
- GSL $27.82
- AVXL $10.60
- Resistance Level
- GSL $29.17
- AVXL $12.68
- Average True Range (ATR)
- GSL 0.48
- AVXL 0.84
- MACD
- GSL -0.08
- AVXL -0.18
- Stochastic Oscillator
- GSL 70.94
- AVXL 6.49
About GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.